"RTF is Highly Unlikely, 50/50 Probability of Approval for 9001" - Cowen Reiterates Sarepta (SRPT) at Ouperform with $114 Price Target

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. GNK
5. USO
6. ARGX
7. AZN
8. SPCX
9. UNG
10. FNGR

Go back to "RTF is Highly Unlikely, 50/50 Probability of Approval for 9001" - Cowen Reiterates Sarepta (SRPT) at Ouperform with $114 Price Target

Sarepta Therapeutics (SRPT) Rallies On BLA Submission Intent

July 29, 2022 10:32 AM EDT

Sarepta Therapeutics (NASDAQ: SRPT) announced Friday it intends to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001.

Sarepta shares rallied over 9% on the news.

The company is seeking approval for the investigational gene therapy developed in partnership with Roche to treat... More